Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).
Juliana Chan outlines current knowledge about the relationship between diabetes and COVID-19, discussing risk factors for poor outcomes in people with both conditions and the need for collaborative efforts to improve patient care (7:09).
ADA 2020 interviews
06-18-2020 | ADA 2020 | Conference coverage | Video
Lead investigator Chris Cannon discusses the VERTIS-CV trial, showing that the SGLT2 inhibitor ertugliflozin is noninferior to placebo for the prevention of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (7:16).
06-15-2020 | ADA 2020 | Conference coverage | Video